Bristol Myers’ Reblozyl franchise surpassed $2 billion in annual sales in 2025, delivering 45 percent year-over-year revenue growth. The erythroid maturation agent recorded $550 million in global sales during the fourth quarter alone, with volume gains of 40 percent in the U.S. and strong uptake across Europe and Japan. This performance helped offset an 8 percent decline in legacy product revenues, where patent expirations and generic competition eroded market share for older hematology and immunology drugs.

Analysts project fourth-quarter revenue of $11.2 billion, up 6 percent year-over-year, and adjusted EPS of $1.10, reflecting efficient cost controls and favorable product mix. Management has guided free cash flow of $7.5 billion for the full year, supported by operating margin expansion of 200 basis points. Key metrics under scrutiny include R&D investment rising 12 percent to $3.4 billion in 2025 and a debt-to-EBITDA ratio of 2.3×, positioning the company for continued pipeline advancement without compromising financial flexibility.

Bristol Myers’ flagship immuno-oncology drug, Opdivo, achieved $6.8 billion in global sales for 2025, growing 10 percent year-over-year on expanded label approvals in renal cell carcinoma and first-line lung cancer. With a late-stage pipeline of eight oncology candidates and three registrational studies read out in 2026, the company anticipates further revenue tailwinds. Investors weighing Buy, Hold or Sell should consider the balanced risk: strong cash flow and pipeline catalysts versus ongoing generic erosion in non-core franchises.